EUVIMEDSkopri EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients

Jens Andreas Sarömba iD, Julian Peter Müller iD, Jolanta Tupiec, Anjali Roeth iD, Berkan Kurt, Florian Kahles, Thea Laurentius, Cornelius Bollheimer, Julia C Stingl iD, Katja S Just iD

British Journal of Clinical Pharmacology · 2025-06 · 91 (6) · 1842-1852

DOI: 10.1002/bcp.70004 ↗

At a glance

Beobachtungsstudie in British Journal of Clinical Pharmacology, published online on 2025-02-16. Written by Jens Andreas Sarömba and 9 co-authors. Institution: Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany. Major MEDLINE topics: Cytochrome P-450 CYP2D6. Cited 14 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY 4.0). Funded by: B. Braun Foundation, Melsungen, Germany, Interdisciplinary Centre for Clinical Research within the faculty of Medicine at RWTH Aachen University, Deutsche Forschungsgemeinschaft.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Aims

Phenoconversion, a genotype‐phenotype mismatch, challenges a successful implementation of personalized medicine. The aim of this study was to detect and determine phenoconversion using the solanidine metabolites 3,4‐seco‐solanidine‐3,4‐dioic acid (SSDA) and 4‐OH‐solanidine as diet‐derived cytochrome P450 2D6 (CYP2D6) biomarkers in a geriatric, multimorbid cohort with high levels of polypharmacy.

Methods

Blood samples and data of geriatric, multimedicated patients were collected during physician counsel (CT: NCT05247814). Solanidine and its metabolites were determined via liquid chromatography/tandem mass spectrometry and used for CYP2D6 phenotyping. CYP2D6 genotyping was performed and activity scores (AS) were assigned. Complete medication intake was assessed. A shift of the AS predicted via genotyping as measured by phenotyping was calculated.

Results

Solanidine and its metabolites were measured in 88 patients with complete documentation of drug use. Patients had a median age of 83 years (interquartile range [IQR] 77‐87) and the majority (70.5%, n = 62) were female. Patients took a median of 15 (IQR 12‐17) medications. The SSDA/solanidine metabolic ratio correlated significantly with the genotyping‐derived AS ( P < .001) and clearly detected poor metabolizers. In the model adjusted for age, sex, Charlson Comorbidity Index and estimated glomerular filtration rate each additional CYP2D6 substrate/inhibitor significantly lowered the expected AS by 0.53 (95% confidence interval 0.85‐0.21) points in patients encoding functional CYP2D6 variants ( R 2 = 0.242).

Conclusions

Phenotyping of CYP2D6 activity by measurement of diet‐derived biomarkers elucidates phenoconversion in geriatric patients. These results might serve as a prerequisite for the validation and establishment of a bedside method to measure CYP2D6 activity in multimorbid patients for successful application of personalized drug prescribing.

Subjects

MeSH terms (MEDLINE)

Cytochrome P-450 CYP2D6AgedAged, 80 and overFemaleHumansMaleGenotypeMultimorbidityPhenotypePolypharmacyPrecision MedicineTandem Mass Spectrometry

Author keywords

CYP2D6biomarkerpharmacogeneticsphenoconversionphenotypingpolypharmacysolanidine

Substances

Cytochrome P-450 CYP2D6

Authors and institutions

  • Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
  • Department of General, Visceral, Pediatric and Transplantation Surgery, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
  • Department of Internal Medicine I - Cardiology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
  • Department of Geriatric Medicine, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
  • Department of Geriatrics, Carl von Ossietzky University of Oldenburg, Oldenburg, Lower Saxony, Germany.

ORCID profiles: Jens Andreas Sarömba, Julian Peter Müller, Anjali Roeth, Julia C Stingl, Katja S Just

Funding

  • B. Braun Foundation, Melsungen, Germany
  • Interdisciplinary Centre for Clinical Research within the faculty of Medicine at RWTH Aachen University
  • Deutsche Forschungsgemeinschaft
  • START Program of the Faculty of Medicine RWTH Aachen University
  • Medizinische Fakultät, RWTH Aachen University
  • RWTH Aachen University

Cite

APA

Sarömba, J. A., Müller, J. P., Tupiec, J., Roeth, A., Kurt, B., Kahles, F., Laurentius, T., Bollheimer, C., Stingl, J. C., & Just, K. S. (2025). Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. British Journal of Clinical Pharmacology, 91(6), 1842-1852. https://doi.org/10.1002/bcp.70004

Vancouver

Sarömba JA, Müller JP, Tupiec J, Roeth A, Kurt B, Kahles F, et al. Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. British Journal of Clinical Pharmacology. 2025;91(6):1842-1852. doi:10.1002/bcp.70004

BibTeX
@article{Sarmba2025,
  author = {Sarömba, Jens Andreas and Müller, Julian Peter and Tupiec, Jolanta and Roeth, Anjali and Kurt, Berkan and Kahles, Florian and Laurentius, Thea and Bollheimer, Cornelius and Stingl, Julia C and Just, Katja S},
  title = {Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {6},
  pages = {1842--1852},
  doi = {10.1002/bcp.70004}
}
Start for free →